SecBot SecBot
DEFA14A ·Filed May 28, 2026

CLRB

Cellectar Biosciences, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed4mo ago SEC0001104659-26-067630
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the outcome of the July 7 annual meeting, particularly Proposal 5 (warrant exercise approval) which could result in significant dilution. The appointment of Nantahala designee Andrew Gu to the Board signals activist/investor influence — watch for further strategic moves or capital allocation changes post-meeting.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
CLRB ▼ -19.75% at T+60d
NEUTRAL call -19.75% · α vs SPY -20.93% · entry $3.14 → $2.52
Entry = T+0 close
May 28, 2026
via day close
T+1d
-5.41%
call -5.41% · α -5.67%
$2.97
settled 5mo ago
T+5d
-17.52%
call -17.52% · α -15.02%
$2.59
settled 5mo ago
T+20d
-17.20%
call -17.20% · α -15.40%
$2.60
settled 4mo ago
T+60d
-19.75%
call -19.75% · α -20.93%
$2.52
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Cellectar Biosciences filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting scheduled for July 7, 2026. The filing notifies stockholders of record as of May 19, 2026, and the Board recommends voting FOR all six proposals, including the election of two Class III directors (Andrew Gu and Douglas J. Swirsky), an increase in shares under the 2021 Stock Incentive Plan, ratification of Deloitte & Touche as auditor, advisory say-on-pay, approval of the exercise of warrants for up to 39,618,078 shares of common stock, and adjournment if needed to solicit additional proxies for the warrant exercise proposal. This filing follows a recent 8-K (May 18, 2026) detailing the appointment of Andrew Gu to the Board, designated by Nantahala Capital Management, and the departure of director Stefan D. Loren.

Key Financial Metrics

Meeting
2026-07-07

Key Facts

  • Annual Meeting to be held virtually on July 7, 2026
  • Record date for stockholders is May 19, 2026
  • Board recommends FOR all six proposals
  • Proposal 1: Election of two Class III directors — Andrew Gu and Douglas J. Swirsky
  • Proposal 2: Increase shares available under 2021 Stock Incentive Plan
  • Proposal 3: Ratify Deloitte & Touche as independent auditor for FY2026
  • Proposal 4: Non-binding advisory vote on named executive officer compensation
  • Proposal 5: Approve exercise of warrants for up to 39,618,078 shares of common stock
  • Proposal 6: Adjourn meeting if needed to solicit additional proxies for Proposal 5
  • Cross-filing context: 8-K filed May 18, 2026, appointed Andrew Gu (Nantahala designee) to Board and disclosed departure of director Stefan D. Loren

Financial Impact

Warrant exercise proposal covers up to 39,618,078 shares of common stock, which could be highly dilutive relative to current market cap of $22M if exercised. No dollar amounts for the warrant exercise or share increase are disclosed in this filing.

dilutionshare count

Risk Factors

  • Potential dilution from warrant exercise of up to 39.6 million shares
  • Shareholder vote outcome uncertain — insufficient votes could delay warrant exercise proposal
  • Activist investor Nantahala Capital now has Board representation, may push for strategic changes

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-067630
Document: 0001104659-26-067630-index-headers.html0001104659-26-067630
Document: 0001104659-26-067630-index.html0001104659-26-067630
Document: 0001104659-26-067630.txt0001104659-26-067630
17 reports for CLRB
Performance horizon
63% Hit rate @ T+60 5 of 8 directional calls Went positive at some point 6 of 9 best @ T+60▲ +27.20%May 6, 2026
Filters
Rows
Reports for CLRB — sortable, filterable
TypeNow
Oct 15, 2026
11d ago
Press Release
BULLISH ★ 6/10
$1.19awaiting T+60—$1.22 (+2.52%)
Aug 13, 2026
10w ago
8-K
NEUTRAL ★ 4/10
$2.48awaiting T+60—$1.22 (−50.81%)
Aug 13, 2026
10w ago
Press Release
NEUTRAL ★ 4/10
$2.48awaiting T+60—$1.22 (−50.81%)
Jun 1, 2026
21w ago
Press Release
BULLISH ★ 7/10
$2.97 $2.54▼ −14.48%▼ −15.71%$1.22 (−58.92%)
May 29, 2026
21w ago
S-1/A
BEARISH ★ 6/10
$3.14 $2.52▲ +19.75%▲ +20.93%$1.22 (+61.15%)
May 28, 2026
21w ago
DEFA14A
NEUTRAL ★ 4/10
$3.14 $2.52▼ −19.75%▼ −20.93%$1.22 (−61.15%)
May 19, 2026
22w ago
S-1
BEARISH ★ 6/10
$3.17 $2.60▲ +17.98%▲ +22.98%$1.22 (+61.51%)
May 14, 2026
23w ago
8-K
MIXED ★ 7/10
$3.20 $2.60▼ −18.75%▼ −22.34%$1.22 (−61.87%)
May 14, 2026
23w ago
Press Release
BULLISH ★ 6/10
$3.20 $2.60▼ −18.75%▼ −22.34%$1.22 (−61.87%)
May 11, 2026
24w ago
Press Release
NEUTRAL ★ 1/10
$3.06 $2.52▼ −17.65%▼ −22.04%$1.22 (−60.13%)
Showing 10 of 17

US Market Status

Market Closed — Opens in 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026